Whether you are looking to invest in innovative life science companies, or you are seeking investment, Scotland, with its strong investment environment is the ideal location to achieve your ambitions.


Between 2009 and 2015, Scotland created more than 170 life sciences start ups with a success rate of 85%, demonstrating Scotland’s supportive environment for Life Sciences ventures. In the same period Scotland generated over 60 university Life Sciences spin-outs, more than any other region of the UK. Edinburgh, Strathclyde and Dundee all feature in the top 10 UK universities generating Life Sciences spin-outs.


Supporting this growth, Scotland has enhanced its investment offering, attracting Epidarex Capital, a £50m venture fund supported by a diverse range of investors, including Eli Lilly’s first venture fund investment within the UK. With 30% of its portfolio in Life Sciences, the Scottish Investment Bank is the most active investor in Life Sciences in the UK.


In the last two years, Scotland has attracted significant international investment through acquisition, achieving profitable exits for investors. Nikon bought medical technology company Optos, which will become the cornerstone of its new medical group. Biopta was acquired by Reprocell, a Japanese stem cell specialist. Medical technology giant Medtronic purchased anaesthesia specialist Aircraft Medical; Merck bought IOmet Pharma; French specialist Sartorius Stedim acquired BioOutsource, and Icelandic prosthetics specialist Ӧssur acquired Touch Bionics.


The Scottish Investment Bank (SIB) offers comprehensive Investor readiness training. SIB investment specialists are an experienced team who can help you identify the most appropriate sources of finance for your business and help you secure a funding package from a range of sources including bank funding, other debt providers, equity and grants. BioCity and MediCity also offer support via their Accelerator Programme for further information on Scotland’s strong evolving investment environment .